Find clinical trials for Chronic Lymphocytic Leukemia in Toronto, ON
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Chronic Lymphocytic Leukemia trials near Toronto, ON, CAN:
100 mg twice daily (bid) in approximately 540 participants with chronic lymphocytic leukemia (CLL). Participants will be e...
Phase 3
Brampton, Ontario, Canada and 108 other locations
The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing o...
Phase 2
St. Catharines, Ontario, Canada and 70 other locations
objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic...
Phase 3
Toronto, Ontario, Canada and 230 other locations
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic...
Phase 3
Brampton, Ontario, Canada and 149 other locations
This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL...
Phase 1, Phase 2
Toronto, Ontario, Canada and 79 other locations
The purpose of this study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzum...
Phase 3
Hamilton, Ontario, Canada and 86 other locations
This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL)...
Phase 3
Toronto, Ontario, Canada and 231 other locations
(CAR) (TBI-2001) for relapsed or refractory CD19+ B-cell lymphoma Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic...
Phase 1
Toronto, Ontario, Canada
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm...
Phase 3
Toronto, Ontario, Canada and 216 other locations
This is a Phase 1/2 dose-escalation study of BTCT4465A (Mosunetuzumab) administered as a single agent and in combination with atezolizumab in partici...
Phase 1, Phase 2
Toronto, Ontario, Canada and 48 other locations
Clinical trials
Research sites
Resources
Legal